A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

NCT01100931 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

42

Enrollment

NIH

Sponsor class

Conditions

NSCLC
Solid Tumors

Interventions

DRUG: YM155
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

National Cancer Institute (NCI)